A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Tamoxifen (Primary) ; Thalidomide (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jul 2019 Biomarkers information updated
- 30 Mar 2010 Actual end date (March 2010) added as reported by ClinicalTrials.gov.
- 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.